SynthesisBMC infectious diseases2026
Global and regional trends in multidrug- or rifampicin-resistant tuberculosis, 2000-2024 with forecasts to 2030: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pediatric Tuberculosis in North Kivu: The Urgency of a Targeted Response to a Forgotten Childhood Disease.Public health challenges · 2026Review
- BCG vaccination and household TB exposure in childhood tuberculosis: a community-based case-control study in rural Bangladesh.BMC infectious diseases · 2026Article
- Epidemiologic and clinical characteristics ofFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTuberculosis remains the world’s leading infectious killer, with 8.2 million new cases reported in 2023. Multidrug- or rifampicin-resistant TB (MDR/RR-TB) continues to drive disproportionate mortality worldwide. To analyze trends in MDR/RR-TB prevalence across World Health Organization (WHO) regions from 2000 to 2024, with Forecasts to 2030.
methodsWe conducted a systematic review and meta-analysis to assess MDR/RR-TB prevalence among tuberculosis patients. Five databases (PubMed, EBSCO, SCOPUS, Web of Science, Google Scholar) were searched for studies published between 01/2010 and 06/2025. Pooled prevalence was estimated using a random-effects model, with heterogeneity quantified via I2 statistics. Subgroup and sensitivity analyses stratified results by age, sex, WHO region, study period, sample size, and TB burden.
resultsOur meta-analysis included 102 studies (4.12 million cases; 66.1% male, weighted mean age 39.47 years [SD 5.7]) across 52 countries. Global pooled MDR-TB prevalence declined significantly from 14.4% (95% CI 9.0–19.8) in 2000–2009 to 2.6% (2.3–2.9) in 2020–2024. Africa reported the highest regional burden: prevalence fell from 31.0% (17.3–44.6) to 4.9% (2.8–7.1) over the same period, exceeding other WHO regions in 2020–2024 (Americas: 1.3%; Europe: 1.4%; South-East Asia: 2.6%). Globally, prevalence was higher among males (12.0%, 10.8–13.3) than females (9.7%, 8.6–10.7) and markedly elevated in previously treated patients (19.8%, 18.2–21.4) versus new cases (5.9%, 5.2–6.6). Africa demonstrated distinct epidemiology: the male-female gap narrowed (males: 16.9% [13.5–20.4]; females: 16.3% [12.7–20.0]), and patients aged < 40 years faced disproportionately high prevalence (16.9% [13.8–20.0] vs. global: 4.9% [4.1–5.7]). Previously treated African patients had the highest burden (26.2%, 19.6–32.8), exceeding the global average (18.2%, 16.4–19.9). The pooled prevalence of MDR/RR-TB among HIV co-infected patients in Africa (22.2% [95% CI 17.2–27.1]) is 2.3-fold higher than the global average excluding Africa (9.7% [8.5–10.9]).
conclusionsWhile global MDR/RR-TB prevalence has significantly declined, Africa continues to bear a disproportionate burden, particularly among retreatment cases, young adults, and HIV-positive patients. These findings highlight the urgent need for targeted interventions in high-burden populations and regions. CLINICAL TRIAL NUMBER: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.